Data Management for Post-Transplant Follow Up

One of the many advances that have been achieved in transplantation care today is the ability of patients to return to their community physicians after a period of time for most of their long term care. While the ability to receive care closer to home has obvious advantages for transplant patients, it can pose challenges for the transplant centers that are responsible for the outcomes as well as for the community physicians who may not be as familiar with transplant specific issues. With the never ending demands on both transplant centers as well as their community partners, an effective way of managing the data flow between the centers and referral sources is imperative. This includes timely communication and recognition of laboratory and imaging studies. Manual transmission and review of these documents can be time consuming, costly and fraught with error, particularly if the paper does not reach the appropriate destination.

Transplant centers today have become quite proficient at the utilization of databases for internal data management and communication. Interfacing outside test results automatically with a program's database allows timely recognition and action on these results so that if intervention needs to be performed, a biopsy or drug adjustment for example, this can be performed in a quicker, more efficient fashion. The end result is not only a better outcome for the patient, but a more engaged referral base that can lead to further relationships. Finally, early recognition of a problem can help prolong both graft and patient survival, favorably impacting a center's results.

About the Author: Dr. John Daller, MD, PhD, FACS

As a former Director of several transplant programs, Dr. Daller has expertise in all aspects of transplant program management, as well as hospital program development including clinical, regulatory, business and administrative leadership via his company Strategic Illuminations. He consults in the area of medical legal review, due diligence and scientific evaluations, as well as utilization review via Daller Consulting. He is also Chief Medical Officer of Concordia Valsource, LLC which provides consultative services to developing biopharmaceutical companies and to Venture Capital groups investing in the health and life sciences. Previously, Dr. Daller was Vice President for Medical Programs in the Transplant Business Unit of Genzyme Corporation.